Tyra Biosciences Reports $256M Cash Runway Through 2027, Details Key Clinical Catalysts
summarizeSummary
Tyra Biosciences reported its fourth quarter and full-year 2025 financial results, announcing a robust cash position of $256.0 million, which is expected to fund operations through at least 2027. The company also detailed its new "dabogratinib 3x3" strategy, prioritizing three late-stage clinical studies in LG-UTUC, IR NMIBC, and achondroplasia, while exiting metastatic bladder cancer to optimize capital allocation. This strategic focus is significant for a clinical-stage biotech. Key upcoming catalysts include interim Phase 2 data readouts for SURF302 (IR NMIBC) by the end of 1H 2026 and for BEACH301 (achondroplasia) in 2H 2026, which will be critical for investor evaluation.
At the time of this announcement, TYRA was trading at $32.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $6.42 to $35.71. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.